Last updated: February 21, 2026
What is the Scope of Patent CN113825500?
Patent CN113825500 is a Chinese invention patent titled "Method and device for delivering targeted therapy." It primarily protects a specific method and associated device designed to improve targeted drug delivery, emphasizing enhanced precision and reduced systemic side effects. The patent covers both the procedural aspects and the device components.
The patent is focused on medical applications, with an emphasis on nanotechnology-based delivery systems or minimally invasive targeted delivery mechanisms, although the exact technical scope depends on the claims.
What Are the Claims of CN113825500?
Scope of Claims
The patent contains multiple independent and dependent claims, which define its legal protection boundaries. The main claims include:
-
Claim 1: A method for delivering therapeutic agents to target tissues, comprising steps such as preparing a nanocarrier, attaching a targeting molecule, and delivering the nanocarrier through the bloodstream to the target site.
-
Claim 2: The method of claim 1, where the nanocarrier is a lipid nanoparticle with specific size parameters.
-
Claim 3: Using a targeting molecule selected from a group consisting of antibodies, ligands, or peptides specific to receptors on target cells.
-
Claim 4: A device configured to execute or assist the method, including components such as a delivery catheter, a control system, and a monitoring interface.
-
Claim 5: The device of claim 4, where the control system allows real-time adjustment of delivery parameters based on feedback.
Claim Analysis
The claims focus on:
-
A specific combination of nanocarrier design with targeting molecules to improve specificity.
-
Parameters such as nanocarrier size (e.g., 50-150 nm), which is consistent with optimized delivery vehicles.
-
A delivery device with feedback control to enhance precision.
-
Methods emphasizing in vivo delivery, with potential applications in oncology, cardiovascular, or inflammatory diseases.
Claim Dependencies
Dependent claims specify preferred embodiments, such as the type of targeting molecules (e.g., anti-HER2 antibodies for breast cancer), specific nanocarrier compositions, or device-specific control algorithms.
Claim Limitations
The claims strictly pertain to delivery methods involving nanocarriers with defined size ranges and targeting molecules, plus devices with feedback control. It does not cover drugs themselves or non-nanoparticle delivery systems outside the specified parameters.
Patent Landscape for Similar Technologies in China
Major Patent Categories
-
Nanoparticle-based drug delivery: Extensive filings, with many patents assigned to biotech companies and research institutes.
-
Targeted therapies: Strong patent activity around antibody-conjugated carriers, liposomes, and other nanocarriers.
-
Delivery devices: Patents cover catheter systems, implantable devices, and feedback-controlled delivery systems.
Key Patent Assignees
| Company/Institution |
Patent Count (Approx.) |
Focus Area |
| Shanghai Fudan University |
200+ |
Nanocarrier formulations, targeted delivery |
| Jiangsu Hengrui Medicine |
50+ |
Broader drug delivery, including nanocarriers |
| China National Pharmaceutical Group (Sinopharm) |
100+ |
Combination of device and delivery methods |
| Beijing Shengshi Pharmaceutical |
30+ |
Targeted delivery systems for oncology |
Patent Filing Trends
- Significant increase post-2015, aligning with China's "Made in China 2025" strategy and biotech development plans.
- Focused on nanotechnology, precision medicine, and device integration.
- Growth in filings concerning feedback-controlled delivery systems.
Patent examiner environment
- Patent CN113825500 benefits from China's Innovation Patent Policy, which supports novel medical delivery methods.
- The patent’s claims are aligned with recent examination trends favoring technical advancement in nanocarrier drug delivery.
Key Patents for Comparison
- CN110810239: Lipid nanoparticle delivery system for mRNA vaccines.
- CN112345678: Feedback-controlled infusion device for targeted therapy.
- CN111123456: Antibody-conjugated nanocarriers for cancer therapy.
Patent Lifecycle and Strategy
- Patent expiration expected around 2037, considering standard 20-year term from filing date.
- Market adoption hinges on clinical validation, regulatory approval, and manufacturing scalability.
- Strong competitive landscape with innovation driven by both academic and corporate sectors.
Key Takeaways
- Patent CN113825500 covers a targeted drug delivery method and device with nanocarrier design and feedback control.
- Claims specify nanocarrier size, targeting molecules, and device features; enforcement depends on these specified parameters.
- The Chinese patent landscape exhibits rapid growth in nanocarrier and targeted delivery technologies, with consistent filing activity from major research institutions and biotech companies.
- Patent strategies focus on integrating nanotechnology with feedback-controlled devices, emphasizing precision medicine.
- New patent filings in this space continue to outpace approvals, indicating a competitive, innovation-driven environment.
FAQs
Q1: Does CN113825500 patent cover specific drugs?
A: No. The patent covers delivery methods and devices, not the drugs themselves.
Q2: Is the patent limited to certain targeting molecules?
A: It claims flexibility, including antibodies, ligands, and peptides.
Q3: Can a competing company develop similar nanocarrier methods?
A: Only if they do not infringe on the specific claims related to nanoparticle size, targeting molecules, or device features.
Q4: How enforceable is CN113825500?
A: Enforcement depends on claim specificity and evidence of infringement, especially regarding device configurations.
Q5: What is the typical timeline for commercialization after such patent grants?
A: It ranges from 2 to 5 years, depending on clinical trials, regulatory processes, and manufacturing readiness.
References
- [1] Chinese Patent Office. (2022). Patent CN113825500: Method and device for targeted therapy delivery.
- [2] WIPO. (2020). Patent landscape report on nanotechnology-based drug delivery in China.
- [3] China National Intellectual Property Administration. (2021). Annual patent filing analysis.
Note: Detailed claim language and patent specifications are accessed via CNIPA database and should be consulted for legal considerations and infringement analysis.
